Background : There were no published data regarding the clinical outcomes of various type drug-eluting stent(DES) following percutaneous coronary intervention (PCI) in Korean real world. We evaluated the two-year outcome of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) and zotarolimus-eluting stent (ZES) for the treatment of coronary artery disease in Korean real world. Methods : A prospective single-center cohort had been enrolled from Nov. 2006 to Jul. 2008 at Gil Medical Center. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 2 year. Stent thromboses (ST) by ARC definition were analyzed. Results : Total 1323 patients (SES=402, PES=379, ZES=301, heterogeneous DES=241) who were completed more than two year were analyzed. Two-year MACE were9.30%, 14.1%, 11.5% and 17.1% in SES-, PES-, ZES- and heterogeneous DES-group, respectively (p=0.289). Cardiac death was 1.0%, 1.1%, 1.0% and 0.9% in EES-, ZES-, SES- and PES-group, respectively (p=0.111). ST was 1.5%, 1.9%, 0% and 0.8% in SES-, PES-, ZES- and heterogeneous DES-group, respectively (p=0.225). Conclusions: 1st and 2nd generation DES (SES ,PES, ZES and heterogeneous DES) showed similar two-year clinical outcomes in terms of MACE in patients with coronary artery disease following PCI in Korean real world.